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The MYCN proto-oncogene is associated with poor outcome across a broad range of
pediatric tumors. While amplification ofMYCN drives subsets of high-risk neuroblastoma
and medulloblastoma, dysregulation of MYCN in medulloblastoma (in the absence of
amplification) also contributes to pathogenesis. Since PI3K stabilizes MYCN, we have
used inhibitors of PI3K to drive degradation. In this study, we show PI3K inhibitors
by themselves induce cell cycle arrest, with modest induction of apoptosis. In screen-
ing inhibitors of PI3K against MYCN, we identified PIK-75 and its derivative, PW-12,
inhibitors of both PI3K and of protein kinases, to be highly effective in destabilizing
MYCN. To determine the effects of PW-12 treatment in vivo, we analyzed a genetically
engineered mouse model for MYCN-driven neuroblastoma and a model of MYCN-
driven medulloblastoma. PW-12 showed significant activity in both models, inducing
vascular collapse and regression of medulloblastoma with prominent apoptosis in both
models. These results demonstrate that inhibitors of lipid and protein kinases can drive
apoptosis in MYCN-driven cancers and support the importance of MYCN as a therapeutic
target.
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Introduction
The MYC family of proto-oncogenes (MYC, MYCN, and MYCL) has been broadly implicated in
cancer. MYC proteins are helix–loop–helix transcription factors, which share a large degree of
homology and function. MYC transcriptionally regulates ~500 core targets with as many as 2000
additional cancer and/or cell type-specific targets, making pharmacologic targeting downstream of
MYCproteins challenging. However,MYCproteins are tightly regulated at the level of protein stabil-
ity through several upstream signaling events (1). TheMYCN gene is amplified or overexpressed in
a number of pediatric cancers including bothmedulloblastoma and neuroblastoma and is a negative
prognostic factor in both diseases (2, 3).
Neuroblastoma is the most common extracranial solid tumor of childhood. High-risk neuroblas-
toma represents about 40% of all patients diagnosed. Despite significant progress in the treatment
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of low- and intermediate-risk patients, survival among children
with high-risk disease remains poor even after significant escala-
tions in the intensity of therapy (4, 5). Amplification of MYCN
occurs in ~25% of patients and is the clearest genetic risk factor
for high-risk disease, making MYCN a prominent candidate for
targeted therapies (6, 7). Targeted expression of MYCN to the
peripheral neural crest of mice results in neuroblastoma tumors
with high penetrance. We have previously shown that indirect
methods of blockingMYCN in these animals have led to decreased
tumor size and improved survival (8, 9).
Medulloblastoma is the most common malignant brain tumor
in children and is divided into four molecular subgroups. MYC
family oncogenes are amplified in ~10% of medulloblastoma
tumors and amplification correlates with poor survival (10–12).
MYCN is highly expressed in two of the medulloblastoma sub-
groups, the Sonic Hedgehog (SHH) group and the Group 4
tumors (13). Using a genetically engineered model (GEM), we
have previously targeted expression of MYCN to the cerebellum
of transgenic mice. These GTML mice are predisposed to SHH-
independent, MYCN-amplified medulloblastoma (14). We have
shown that transient downregulation of MYCN in these mice
resulted in tumor cell senescence and improved survival (14, 15).
In addition, medulloblastoma tumor cell lines with constitutive
activation of the SHHpathway derived fromPtc1+/ p53 / mice
(SmoWT) (16–18), demonstrate robust tumorigenesis (17). Loss
of the Ptch receptor in these mice leads to constitutive activation
of the downstream smoothened transmembrane protein, resulting
in medulloblastomas driven by MYCN and GLI. This model pro-
vides an excellent platform to exploreMYCN-directed pre-clinical
therapeutics in neuroblastoma and in medulloblastoma.
As transcription factors with no surfaces amenable to small
molecule binding, MYC proteins are widely considered undrug-
gable directly. However, the stability of MYCN protein is tightly
regulated by a sequential series of key phosphorylation events
downstream of CDK1/CyclinB and the PI3K/mTOR pathway,
suggesting inhibitors of relevant kinases as an approach to target
MYC and MYCN (1). Further, these phosphorylation events are
known to be downstream of the activating ALKF1174L mutation,
which plays a role in both sporadic and familial neuroblastomas
(19). We have previously shown that the tool PI3K inhibitor
LY294002 and the dual PI3K/mTOR inhibitorNVP-BEZ235 cause
downregulation of MYCN protein and, in the case of NVP-
BEZ235, decreased angiogenesis through a paracrine signaling
mechanism (9, 20). These studies emphasize the importance of
mouse models for MYCN-driven pediatric cancers and implicate
further exploration of the interplay between PI3K and MYCN
protein regulation through the use of alternate pharmacologic
inhibitors of PI3K.
Several specific inhibitors of PI3K have been developed and
characterized in other systems including PI-103, PIK-75, PW-12,
and BEZ235 (21, 22). Resistance to PI3K inhibitors is scaffold-
dependent and often mediated by point mutations (23). If PI3K
inhibition is to be a viable strategy in cancer, demonstration of
efficacy across an array of PI3K inhibitor scaffolds will likely be
necessary.We have previously shown efficacy for the PI3K/mTOR
inhibitor BEZ235 in neuroblastoma (9). In the current study, we
show that the PI3K alpha inhibitor PIK-75 and its derivative,
PW-12, destabilize MYCN protein and induce cell cycle arrest
and apoptosis in MYCN-amplified cell lines. We further demon-
strate that these drugs have pre-therapeutic efficacy in models
of MYCN-driven neuroblastoma (24) and MYCN-driven medul-
loblastoma (16, 25). These studies provide evidence for PI3K
inhibition with subsequent blockade of MYCN and vascular col-
lapse as a therapeutic strategy across chemical scaffolds and an
impetus for the continued development of PI3K inhibitors in
MYCN-driven pediatric cancers, including both neuroblastoma
and medulloblastoma.
Materials and Methods
Immunoblotting
Human Kelly neuroblastoma cell lines were obtained from the
University of California at San Francisco. Cells were grown
in RPMI medium with 10% FBS at 37°C. In most experi-
ments, cells were conditioned in 2% FBS for 5 h and replaced
with full medium and recombinant human insulin-like growth
factor-I (20 ng/ml) (Invitrogen, Waltham, MA, USA) for 1 h
before harvesting. Lysates were collected and sonicated. Primary
antibodies were as follows: anti-MYCN, anti-phosphorylated
Akt, anti-p-rpS6, anti-Akt, anti-rpS6 (Cell Signaling Technol-
ogy, Danvers, MA, USA), and β-tubulin (Upstate, Buffalo, NY,
USA). Immunoblotswere developedwith horseradish peroxidase-
conjugated secondary antibodies (Calbiochem, San Diego, CA,
USA) and Enhanced Chemiluminescence Plus reagents (Amer-
sham, Piscataway, NJ, USA).
Cell Proliferation Assay and Flow Cytometry
Kelly neuroblastoma cells were suspended in basal RPMImedium
with 10% FBS and plated in 96-well tissue culture plates
(Corning/Sigma-Aldrich, Tewksbury, MA, USA). To measure
viable cells, Kelly cells were incubated at 37°C for 16 h and then
changed into fresh medium containing LY-294002 (Sigma, St.
Louis, MO, USA), PI-103 (Calbiochem, San Diego, CA, USA),
PIK-75, PW-12 (Kevan Shokat, Ph.D. Lab, University of California
San Francisco, CA, USA), or DMSO vehicle. We analyzed DNA
content at 48 h after plating using Water Soluable Tetrazolium
(WST-1) Cell Proliferation Assay Kit (Invitrogen, Grand Island,
NY, USA) according to the manufacturer’s protocol. In this assay,
A450 nm A800 nm is proportional to secreted WST-1 activity and
proliferation. In addition, cell cycle effects were measured using
flow cytometry as previously described in our lab (26). For these
experiments, Kelly neuroblastoma cells were treated for 48 h with
1µM of PI-103 or PW-12.
Neuroblastoma Genetically Engineered Mouse
Model
TH-MYCN transgenic mice were maintained in hemizygotic mat-
ings as previously described (24). All animals were housed and
treated following University of California at San Francisco Insti-
tute on Animal Care and Use Committee (IACUC) guidelines.
TH-MYCN mice with neuroblastoma tumors were treated either
with 25mg/kg PW-12 in 10% DMSO/water (n= 3) or vehicle
alone [10% DMSO/water (n= 3)], once daily by IP injection, for
14 days. ForWestern blot analysis, tumors were snap-frozen at the
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time of harvesting. For immunohistochemistry, tumors were fixed
in 10% formalin for 24 h and processed as described below. For
tumor weight assessment, tumors were weighed on the final day
of treatment, 14 days. Tumor diameters were measured on day 14
and volumes were calculated (mm3=width2 length/2).
SHH Medulloblastoma Subgroup Tumor Model
All athymic nude mice were obtained from Jackson Laboratories
(Bar Harbor, ME, USA), and were housed and treated following
University of California at San Francisco Institute on Animal Care
and Use Committee (IACUC) guidelines. About 6 106 SmoWT
medulloblastoma cells derived from medulloblastoma tumors
generated from Ptc1+/ p53+/  mice (16–18) were injected sub-
cutaneously into the flank of athymic nude mice. A total of 10
mice were used for these experiments. Starting 8 h after implan-
tation of cells, five animals were treated with 25mg/kg PW-12
in 10% DMSO/water and five were treated with vehicle alone
[(10%DMSO/water)], once daily by IP injection for 7 days. Tumor
diameters were measured with calipers daily and volumes were
calculated (mm3=width2 length/2).
Histology
ForH&Eanalysis, 10-µmsectionswere cut paraffin blocks.Hema-
toxylin (Vector Labs, Burlingame, CA, USA) and bluing agent
was added. Slides were washed three times with water and once
with 70% ethanol (EtOH) for 5min each. Eosin was added fol-
lowed by 70, 95, and 100% EtOH, and dipped into xylene. Slides
were mounted with Vectashield (Vector Labs) and analyzed with
light microscopy. For immunohistochemistry, samples were pre-
pared as described previously (20) using the following antibodies:
Ki67 (1:200; M7249; Dako, Carpinteria, CA, USA), Ki67 (1:100;
NB600-1252; Novus Biologicals, Littleton, CO, USA), cleaved-
Caspase-3 (1:200; 9661; Cell Signaling Technology, Danvers, MA,
USA), MYCN (1:50; 10159-2-AP; Proteintech, Chicago, IL, USA),
and CD-31 (1:50; 55024; BD Bioschences, San Diego, CA, USA).
Statistical Analysis
To evaluate in vivo data, averages were calculated and error bars
were generated using SD. Student’s t-test was used to calculate sta-
tistical significance. A p-value <0.05 was considered statistically
significant.
Results
Both PIK-75 and PW-12 Potently Downregulate
MYCN Protein
In order to assess the effects of pharmacologic inhibition of PI3K
on MYCN-driven cells, human Kelly MYCN-amplified neurob-
lastoma cells were treated with various PI3K inhibitors: PI-103,
LY-294002, PIK-75, and PW-12. PI-103 causes proliferative arrest
but not apoptosis during in vivo glioma treatment (26). It acts by
blocking class I PI3Ks and mTOR, and subsequent downstream
stabilization of MYCN protein. LY-294002 also causes prolifer-
ative arrest but not apoptosis. It is also a pan-selective, broad-
spectrum PI3K/mTOR inhibitor that blocks both p-Akt and the
downstream target of mTOR p-rpS6 (22). LY-294002 is associated
with significant cellular toxicity and therefore has limited effect as
viable human clinical in vivo agent (26, 27). However, in xenograft
models of neuroblastoma and glioma, it has been shown to effec-
tively block progression of tumorigenesis though not apoptosis
(26, 28, 29). PIK-75 is a PI3 kinase alpha selective inhibitor, specif-
ically, it is an imidazopyridine inhibitor that induces apoptosis,
not growth arrest, in glioma cells (29). However, this inhibitor
carries significant cellular toxicitywith broad off-target effects and
therefore is not a viable clinical therapeutic option. Because of this,
PIK-75 is an effective agent to study in vitro, but is toxic in vivo.
PW-12, a derivative of PIK-75, induces growth arrest as well as
some apoptosis. It has fewer off-target effects than its counterpart
and therefore is a viable option for in vivo animal and human
clinical therapeutics.
Human Kelly MYCN-amplified neuroblastoma cells were
treated with increasing concentrations of PIK-75 or PW-12
and blotted for markers of PI3K activity and MYCN protein
(Figure 1A). These two drugs were chosen from the PI3K panel
because PIK-75 is a highly effective in vitro inhibitor but due to
known toxicity is not a viable in vivo option. PW-12, however, is
a less toxic derivative of PIK-75. There is clear downregulation
of MYCN in response to both PIK-75 and PW-12 (Figure 1A).
This corresponds directly with concomitant downregulation of
AKT phosphorylation downstream of PI3K. These data indicate
that the stability of MYCN protein is sensitive to inhibition of
PI3K alpha in vitro as well as some mTOR inhibition as evidenced
by blockade of p-rpS6. Further, blockade of PI3K by PIK-75
results in a significant decrease in viability in MYCN-amplified
FIGURE 1 | Inhibitors of PI3K downregulate MYCN protein, increase
apoptosis, and decrease viability in MYCN-amplified tumor cells.
(A) Kelly MYCN-amplified neuroblastoma cells were treated for 24 h with the
indicated concentrations of inhibitor (PIK-75 or PW-12) and blotted for MYCN
and markers downstream of PI3K (pAKT) and mTOR (prpS6). (B) Kelly
neuroblastoma cells were treated with inhibitor (LY-294002, PI-103, PIK-75,
PW-12, or DMSO) for 48 h and cell proliferation was measured by WST1
assay. (C) Kelly neuroblastoma cells were treated with 1µM of inhibitor
(PI-103, PW-12) for 48 h and cell cycle effects were analyzed by flow
cytometry.
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FIGURE 2 | PW-12 is efficacious in a GEM model of MYCN-amplified
neuroblastoma. Tumor-bearing TH-MYCN mice were treated for 14 days
with either 25mg/kg of PW-12 (n=3) or vehicle alone (n= 3). (A) Western
blot for MYCN protein from treated tumors confirm that PW-12 is effective at
downregulating MYCN protein production. (B) Tumor size was significantly
reduced in treated animals (* represents p<0.05). (C) Histology for Ki67 and
c-Caspase 3 shows increase in apoptosis and decrease in proliferation in
treated tumors.
cells (Figure 1B) when PW-12 and PIK-75 are compared to
LY294002 (a tool compound PI3K/mTOR inhibitor with lower
affinity for these kinases) or PI-103, a PI3K/mTOR inhibitor with
intermediate activity.
Next, we explored two PI3K inhibitors to evaluate effects on cell
cycle, PI-103 and the PIK-75 derivative PW-12. Thesewere chosen
because their low-toxicity profiles make them more viable ther-
apeutic options than their counterparts. When compared to the
control, PW-12 demonstrated significant apoptosis, as measured
by flow cytometry and measurement of the sub-G1/G0 fraction
(Figure 1C), suggesting increased apoptosis as one contributor to
the increase in activity when comparing PW-12 to PI-103 and to
vehicle. This loss of cells to apoptosis could explain the differences
in cell cycle profiles between PI-103 and PW-12. Notably, MYCN
is critical for S-phase entry inMYCN-drivendisease andbothPW-
12 and PIK-75 result in a loss of cells in S-phase and accumulation
of cells in G1, perhaps because of increased potency against PI3K
by PW-12 in these cells (Figure 1A). In addition, the smaller
percentage of Kelly neuroblastoma cells treated with PW-12 are
in the S and M phases of the cell cycle suggesting decreased
proliferation.
FIGURE 3 | PW-12 is efficacious in an orthotopic flank tumor model of
MYCN-amplified medulloblastoma. Mice were implanted with 6106
SmoWT medulloblastoma cells in the hindflank. Animals were treated for
7 days with 25mg/kg of PW-12 (n= 5) or vehicle alone (n= 5). (A) Tumor size
was significantly reduced in treated animals (all time points days 1–7 resulted
in statistically significant differences between the treatment and control
groups). (B) Histology on H&E stain is consistent with medulloblastoma (H&E,
20). Tumor cell proliferation (Ki67, 40) was decreased, apoptosis
(cleaved-caspase-3, 40) increased, MYCN (20) expression
downregulated, and vascularity decreased in PW-12 treated tumors as
confirmed by histology (B) and cell quantification for apoptosis and cell
proliferation (C). (* represents p<0.05).
PI3K Inhibition by PW-12 has Efficacy in a
TH-MYCN Model of Neuroblastoma
Using the TH-MYCN neuroblastoma mouse model in which
human MYCN is expressed under control of the mouse tyrosine
hydroxylase promoter, we are able to generate mouse neuroblas-
toma tumors with high penetrance, which are genetically, histo-
logically, and morphologically similar to human neuroblastomas
(24). Abdominal tumors were detected in TH-MYCNmice by pal-
pation and either PW-12 (25mg/kg) or vehicle alone was admin-
istered by IP injection daily for 14 days. PW-12 treated tumors
demonstrate a significant decrease in MYCN protein expression
and in tumor mass (p< 0.05) when compared to vehicle treated
controls (Figures 2A,B), consistentwith direct blockade ofMYCN
and subsequent anti-tumor effects. They also showed decreased
cellularity, decreased proliferation measured by Ki-67 staining,
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and increased apoptosis as measured by cleaved caspase 3 staining
(Figure 2C). These results support the role of PW-12 in neuroblas-
toma tumor regression, thereby positioning it to be a pre-clinical
therapeutic for MYCN-driven neuroblastoma.
PI3K Inhibition by PW-12 has Efficacy in a
MYCN-Driven SHH Medulloblastoma
To study MYCN-driven medulloblastoma, we used a subcuta-
neous flank allograft model where SmoWT cells were injected
in to the flank of athymic nude mice. In this model, SmoWT
cells from tumors of Ptc1+/ p53+/  mice undergo tumorigen-
esis via activation of the Shh pathway. Allografted animals were
treated with either PW-12 (25mg/kg) or vehicle by IP injection
daily for 7 days. In response to therapy, treated tumors showed
a statistically significant (p< 0.05) decrease in tumor volume
(Figure 3A) with preserved medulloblastoma histology features
on H&E (Figure 3B). The small amount of tumor mass in the
treated tumors precluded us from immunoblotting these spec-
imens. However, immunohistochemistry revealed uniform and
profoundly decreased levels of MYCN across tumors in all five
mice treatedwith PW-12 aswell as decreased vascularity in treated
tumors as measured by CD-31 compared to untreated tumors
(Figure 3B). In addition, treated tumors showed a clear decrease
in cell proliferation by Ki67 and marked induction of apopto-
sis, cleaved caspase (Figures 3B,C). These results establish the
flank SmoWT tumor cell implantation as a useful model for pre-
clinical therapeutics in medulloblastoma and suggest a potential
for inhibitors of PI3K in children withMYCN-driven disease.
Discussion
Effective pharmacologic targeting of theMYC family of transcrip-
tion factor oncogenes, particularly targeting MYCN in pediatric
cancer, has been a long sought after goal (1). Pre-clinical test-
ing of drugs across pharmacologic scaffolds is an indicator of
robustness of a particular drug target and mechanism as well as a
potentialmeans of bypassing emergent resistance. PI3K inhibition
has previously been implicated in stabilization ofMYCN.Here, we
show that PW-12, a bioavailable derivative of the PI3K inhibitor
PIK-75, shows knockdown of MYCN in a neuroblastoma cell
line with marked reduction in viability and changes in cell cycle
consistent with a MYCN-specific effect. Using a transgenic model
ofMYCN-amplified neuroblastoma and a model of medulloblas-
toma where murine-derived allografted cells are implanted into
mice, we demonstrate significant in vivo efficacy against both neu-
roblastoma and medulloblastoma tumors. We further show on-
target efficacy against tumor MYCN protein, marked decrease in
proliferation and increase in tumor apoptosis as well as apparent
tumor vascular collapse.
The past decade of experience with targeted inhibitors has
shown that emergent resistance is nearly inevitable. Effective
blockade of a particular pharmacologic target requires an array
of pharmacologic scaffolds to bypass resistance by point mutation
within the target, a resistance mechanism that has been shown
to be active for PI3K inhibitors (23). To our knowledge, this is
the first in vivo pre-therapeutic trial of PW12 in neuroblastoma
or medulloblastoma and the first implicating blockade of MYCN
in its effect. By broadening in vivo and cell line studies across
this new pharmacologic scaffold, these studies add to the growing
evidence implicating PI3K/mTOR inhibition as a viable strategy
inMYCN-driven pediatric cancers including both neuroblastoma
and medulloblastoma.
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